1. Home
  2. BGY vs DCTH Comparison

BGY vs DCTH Comparison

Compare BGY & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Enhanced International Dividend Trust

BGY

Blackrock Enhanced International Dividend Trust

N/A

Current Price

$5.39

Market Cap

530.1M

Sector

Finance

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$14.76

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BGY
DCTH
Founded
2007
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
530.1M
578.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BGY
DCTH
Price
$5.39
$14.76
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $24.00
AVG Volume (30 Days)
★ 314.4K
248.2K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 7.41%
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
$24.61
Revenue Next Year
N/A
$24.27
P/E Ratio
★ N/A
$362.50
Revenue Growth
N/A
N/A
52 Week Low
$5.19
$8.12
52 Week High
$6.23
$17.42

Technical Indicators

Market Signals
Indicator
BGY
DCTH
Relative Strength Index (RSI) 36.35 45.82
Support Level $5.19 $14.52
Resistance Level $5.85 $16.51
Average True Range (ATR) 0.08 0.48
MACD -0.01 -0.01
Stochastic Oscillator 19.57 45.76

Price Performance

Historical Comparison
BGY
DCTH

About BGY Blackrock Enhanced International Dividend Trust

Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: